{"id":"rabeprazole-enteric-coated-tablets","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Headache"},{"rate":"2-5","effect":"Diarrhea"},{"rate":"2-5","effect":"Nausea"},{"rate":"1-3","effect":"Abdominal pain"},{"rate":"1-3","effect":"Constipation"},{"rate":"1-2","effect":"Rash"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Rabeprazole binds to and inactivates the proton pump (H+/K+-ATPase) on the secretory surface of gastric parietal cells, preventing the final step of gastric acid production. This leads to sustained reduction of intragastric acidity, allowing healing of acid-damaged tissues and relief of acid-related symptoms. The enteric coating delays release until the tablet reaches the small intestine, protecting the drug from gastric acid degradation and improving bioavailability.","oneSentence":"Rabeprazole is a proton pump inhibitor that suppresses gastric acid secretion by irreversibly blocking the H+/K+-ATPase enzyme in gastric parietal cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:31:11.207Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Gastroesophageal reflux disease (GERD)"},{"name":"Peptic ulcer disease"},{"name":"Zollinger-Ellison syndrome"},{"name":"Acid-related dyspepsia"}]},"trialDetails":[{"nctId":"NCT07339956","phase":"EARLY_PHASE1","title":"Yiwei Jiaohuang Ointment for Gastrointestinal Bleeding Associated With Oral Antithrombotic Agents","status":"NOT_YET_RECRUITING","sponsor":"China-Japan Friendship Hospital","startDate":"2026-01-10","conditions":"Gastrointestinal Bleeding","enrollment":60},{"nctId":"NCT05857163","phase":"PHASE3","title":"Efficacy and Safety of Rifasutenizol (TNP 2198), Rabeprazole and Amoxicillin in Participants With H. Pylori Infection","status":"COMPLETED","sponsor":"TenNor Therapeutics (Suzhou) Limited","startDate":"2023-05-18","conditions":"H.Pylori Infection","enrollment":700},{"nctId":"NCT05899829","phase":"PHASE1","title":"Evaluation of the Effect of Rifampin and Rabeprazole on the Pharmacokinetics of Camlipixant","status":"COMPLETED","sponsor":"Bellus Health Inc. - a GSK company","startDate":"2023-06-21","conditions":"Cough, Healthy","enrollment":42},{"nctId":"NCT06481371","phase":"NA","title":"Zuojin Wan Combined With Rabeprazole or Mosapride for the Treatment of Functional Dyspepsia Combined With Depression","status":"NOT_YET_RECRUITING","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2024-06-30","conditions":"Functional Dyspepsia, Depression","enrollment":120},{"nctId":"NCT06337604","phase":"PHASE1","title":"The Safety and Tolerability, Pharmacokinetics of TNP-2092 Capsules in Combination With Rabeprazole Sodium Enteric-coated Tablets","status":"COMPLETED","sponsor":"TenNor Therapeutics Inc.","startDate":"2017-10-10","conditions":"Helicobacter Pylori Infection","enrollment":20},{"nctId":"NCT05630677","phase":"PHASE1","title":"A Study to Compare Bioavailability of AZD5055 Film-coated Tablet With AZD5055 Oral Suspension and to Assess the Effect of Food and an Acid Reducing Agent on Pharmacokinetics (PK) of AZD5055 in Healthy Subjects.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-11-04","conditions":"Healthy Volunteers","enrollment":21},{"nctId":"NCT05879029","phase":"PHASE4","title":"Clinical Study of Jinsang Liyan Capsules Combined With PPI in the Treatment of LPRD","status":"UNKNOWN","sponsor":"Tongji Hospital","startDate":"2023-07-01","conditions":"Laryngopharyngeal Reflux","enrollment":72},{"nctId":"NCT06076694","phase":"PHASE2","title":"Efficacy and Safety After Multiple Doses of TNP-2198 Capsules, Rabeprazole Sodium Enteric-coated Tablets and Amoxicillin Capsules in Helicobacter Pylori Infected-positive Participants","status":"COMPLETED","sponsor":"TenNor Therapeutics (Suzhou) Limited","startDate":"2022-06-26","conditions":"Helicobacter Pylori Infection","enrollment":80},{"nctId":"NCT06076681","phase":"PHASE1, PHASE2","title":"A Study to Evaluate Preliminary Helicobacter Pylori Eradication After Multiple Doses of TNP-2198 Capsules Combined With Rabeprazole Sodium Enteric-coated Tablets, or Rabeprazole Sodium Enteric-coated Tablets and Amoxicillin Capsules","status":"COMPLETED","sponsor":"TenNor Therapeutics (Suzhou) Limited","startDate":"2021-09-27","conditions":"Helicobacter Pylori Infection","enrollment":40},{"nctId":"NCT05604261","phase":"PHASE2","title":"A Study of Anaprazole Sodium Enteric-coated Tablets in the Treatment of Reflux Esophagitis","status":"UNKNOWN","sponsor":"Xuanzhu Biopharmaceutical Co., Ltd.","startDate":"2022-12","conditions":"Reflux Esophagitis, Gastroesophageal Reflux, Esophagitis","enrollment":156},{"nctId":"NCT04157881","phase":"PHASE4","title":"A Study on the Impact of Rabeprazole-induced Elevated Stomach pH on APO-Dabigatran Exposure in Healthy Volunteers","status":"COMPLETED","sponsor":"Population Health Research Institute","startDate":"2020-01-03","conditions":"Atrial Fibrillation, Venous Thromboembolism","enrollment":46},{"nctId":"NCT04471922","phase":"PHASE1","title":"A Multiple Ascending High Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects","status":"COMPLETED","sponsor":"Sihuan Pharmaceutical Holdings Group Ltd.","startDate":"2019-03-21","conditions":"Healthy Volunteers","enrollment":45},{"nctId":"NCT03037606","phase":"PHASE4","title":"Comparison of the Effect of Rabeprazole 50 mg DDR Capsules and 20 mg Enteric-coated Tablets","status":"COMPLETED","sponsor":"Neutec Ar-Ge San ve Tic A.Ş","startDate":"2017-08-01","conditions":"Gastroesophageal Reflux Disease","enrollment":48},{"nctId":"NCT02605395","phase":"PHASE4","title":"Bioequivalence Study of Raperazole 20mg DR Tabs and PARIET® 20 mg DR Tabs Under Fed Conditions","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-03-22","conditions":"Gastrointestinal Diseases","enrollment":70},{"nctId":"NCT02446483","phase":"PHASE4","title":"A Bioequivalence Study of Idiazole 20mg DR Tabs and PARIET® 20 mg DR Tabs After a Single Oral Dose Administration Under Fasting Conditions in Healthy Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-03-19","conditions":"Gastrointestinal Diseases","enrollment":60},{"nctId":"NCT02689999","phase":"PHASE4","title":"The Effect of Dexrabeprazole on Intragastric and Intraesophageal Acidity","status":"COMPLETED","sponsor":"Neutec Ar-Ge San ve Tic A.Ş","startDate":"2016-02","conditions":"Gastroesophageal Reflux Disease (GERD)","enrollment":12},{"nctId":"NCT02477306","phase":"PHASE1","title":"A Bioequivalence Study of Rabeprazole From Idiazole 20mg DR Tabs (GSK, Egypt) and PARIET 20 mg DR Tabs (JANSSEN, EGYPT)","status":"COMPLETED","sponsor":"Genuine Research Center, Egypt","startDate":"2014-03","conditions":"Healthy","enrollment":60},{"nctId":"NCT01990586","phase":"PHASE1","title":"Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Rabeprazole Sodium Delayed Release Tablets Under Fed Conditions","status":"COMPLETED","sponsor":"Torrent Pharmaceuticals Limited","startDate":"","conditions":"Healthy","enrollment":""},{"nctId":"NCT01990378","phase":"PHASE1","title":"Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Rabeprazole Sodium Delayed Release Tablets Under Fasted Conditions","status":"COMPLETED","sponsor":"Torrent Pharmaceuticals Limited","startDate":"","conditions":"Healthy","enrollment":""},{"nctId":"NCT01513785","phase":"PHASE2","title":"New Dual Therapy for Primary Treatment of Helicobacter Pylori Infection：a Pilot Study","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2011-04","conditions":"Functional Dyspepsia","enrollment":40},{"nctId":"NCT00236184","phase":"PHASE3","title":"E3810-A001-313: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2005-10","conditions":"Heartburn","enrollment":629}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"CROHN^S DISEASE"},{"count":1,"reaction":"PLATELET COUNT DECREASED"}],"_approvalHistory":[],"publicationCount":12,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Rabeprazole"],"phase":"phase_3","status":"active","brandName":"Rabeprazole Enteric-Coated Tablets","genericName":"Rabeprazole Enteric-Coated Tablets","companyName":"China-Japan Friendship Hospital","companyId":"china-japan-friendship-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rabeprazole is a small molecule medication used to treat conditions such as Functional Dyspepsia, Gastroesophageal Reflux Disease, and Helicobacter Pylori Infection. It is an acid pump inhibitor that works by reducing the amount of acid produced in the stomach.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}